Related Experiment Video

Updated: May 18, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action

Karima Bettayeb1, Nassima Oumata, Yuanyuan Zhang

  • 1Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Ave., New York, NY 10021, USA.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|September 14, 2012
PubMed

Insights

Researchers identified Aftin-4, a compound that selectively increases toxic amyloid-beta 42 (Aβ42) peptide production, a key factor in Alzheimer's disease (AD). This discovery suggests a common mechanism underlying Aβ42 elevation in AD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • The precise pathways driving the production of toxic amyloid-beta 42 (Aβ42) peptide, a critical factor in Alzheimer's disease (AD), remain largely unknown.
  • Understanding these pathways is crucial for developing effective therapeutic strategies against AD.

Purpose of the Study:

  • To identify novel compounds and pathways that modulate Aβ42 production.
  • To elucidate the molecular mechanisms by which certain compounds exacerbate AD pathology.

Main Methods:

  • Utilized cell-based assays (N2a cells, primary neurons) and brain lysates to quantify Aβ42 levels.
  • Employed affinity chromatography and mass spectrometry to identify Aftin-4 interacting proteins.
  • Conducted electron microscopy and sucrose gradient fractionation to analyze cellular and subcellular effects.

Main Results:

  • Identified Aftin-4, a compound that selectively and potently increases Aβ42 production (7-fold in N2a cells) with an EC50 of 30 μM.
  • Discovered that Aftin-4 interacts with VDAC1, prohibitin, and mitofilin, proteins implicated in AD.
  • Observed that Aftin-4 induces mitochondrial dysfunction and perturbs γ-secretase localization, similar to other known 'AD accelerator' compounds.

Conclusions:

  • Aftin-4 represents a novel tool for studying Aβ42 production pathways in Alzheimer's disease.
  • The identified protein targets (VDAC1, prohibitin, mitofilin) and observed cellular effects suggest a common mechanism of action for Aβ42-raising agents.
  • These findings provide new insights into AD pathogenesis and potential therapeutic targets.

More Related Videos

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...